Guggenheim Capital’s AstraZeneca AZN Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q1
$2.78M Sell
14,101
-83,700
-86% -$16.1M 0.02% 606
2025
Q4
$18M Buy
97,801
+2,269
+2% +$398K 0.13% 149
2025
Q3
$14.7M Sell
95,532
-1,648
-2% -$249K 0.11% 193
2025
Q2
$13.6M Buy
97,180
+15,550
+19% +$2.18M 0.11% 194
2025
Q1
$12M Sell
81,630
-18,127
-18% -$2.62M 0.11% 195
2024
Q4
$13.1M Sell
99,757
-3,918
-4% -$549K 0.11% 190
2024
Q3
$16.2M Sell
103,675
-6,015
-5% -$971K 0.11% 180
2024
Q2
$17.1M Buy
109,690
+1,003
+0.9% +$151K 0.12% 162
2024
Q1
$14.7M Sell
108,687
-2,720
-2% -$360K 0.1% 198
2023
Q4
$15M Buy
111,407
+3,029
+3% +$394K 0.11% 188
2023
Q3
$14.7M Buy
108,378
+10,043
+10% +$1.37M 0.13% 177
2023
Q2
$14.1M Sell
98,335
-3,357
-3% -$494K 0.11% 196
2023
Q1
$14.1M Buy
101,692
+2,913
+3% +$392K 0.12% 188
2022
Q4
$13.4M Sell
98,779
-16,168
-14% -$2.03M 0.12% 202
2022
Q3
$12.6M Sell
114,947
-4,068
-3% -$516K 0.12% 208
2022
Q2
$15.7M Sell
119,015
-14,911
-11% -$1.96M 0.12% 193
2022
Q1
$17.8M Sell
133,926
-5,378
-4% -$645K 0.11% 220
2021
Q4
$16.2M Sell
139,304
-33,582
-19% -$3.95M 0.08% 258
2021
Q3
$20.8M Buy
172,886
+149,298
+633% +$17.4M 0.12% 170
2021
Q2
$2.83M Buy
23,588
+863
+4% +$94.7K 0.02% 917
2021
Q1
$2.26M Buy
22,725
+3,923
+21% +$394K 0.01% 961
2020
Q4
$1.88M Buy
18,802
+8,246
+78% +$873K 0.01% 998
2020
Q3
$1.16M Sell
10,556
-2,863
-21% -$318K 0.01% 1148
2020
Q2
$1.42M Buy
13,419
+2,606
+24% +$269K 0.01% 1037
2020
Q1
$965K Sell
10,813
-2,031
-16% -$191K 0.01% 1106
2019
Q4
$1.28M Buy
12,844
+185
+1% +$17.4K 0.01% 1238
2019
Q3
$1.13M Sell
12,659
-6,459
-34% -$560K 0.01% 1270
2019
Q2
$1.58M Sell
19,118
-6,254
-25% -$490K 0.01% 1150
2019
Q1
$2.05M Buy
25,372
+3,934
+18% +$310K 0.02% 1058
2018
Q4
$1.63M Sell
21,438
-8,438
-28% -$659K 0.01% 1145
2018
Q3
$2.36M Buy
29,876
+305
+1% +$23.1K 0.02% 1143
2018
Q2
$2.08M Buy
29,571
+226
+0.8% +$16.3K 0.01% 1234
2018
Q1
$2.05M Sell
29,345
-45,515
-61% -$3.15M 0.01% 1617
2017
Q4
$5.2M Sell
74,860
-12,789
-15% -$862K 0.01% 1016
2017
Q3
$5.94M Buy
87,649
+37,905
+76% +$2.39M 0.01% 961
2017
Q2
$3.39M Sell
49,744
-44,524
-47% -$2.91M 0.01% 1242
2017
Q1
$5.87M Buy
94,268
+44,694
+90% +$2.6M 0.02% 933
2016
Q4
$2.71M Sell
49,574
-43,004
-46% -$2.44M 0.01% 1443
2016
Q3
$6.08M Sell
92,578
-5,322
-5% -$348K 0.02% 906
2016
Q2
$5.91M Buy
97,900
+2,665
+3% +$155K 0.02% 903
2016
Q1
$5.36M Sell
95,235
-18,303
-16% -$1.1M 0.02% 956
2015
Q4
$7.71M Sell
113,538
-63,841
-36% -$4.19M 0.02% 847
2015
Q3
$11.3M Sell
177,379
-150,661
-46% -$9.91M 0.03% 706
2015
Q2
$20.9M Sell
328,040
-86,957
-21% -$5.95M 0.05% 606
2015
Q1
$28.4M Sell
414,997
-25,737
-6% -$1.79M 0.07% 537
2014
Q4
$31M Sell
440,734
-100,803
-19% -$7.22M 0.08% 467
2014
Q3
$38.7M Buy
541,537
+95,785
+21% +$7.01M 0.09% 336
2014
Q2
$33.1M Buy
445,752
+55,521
+14% +$4.01M 0.08% 416
2014
Q1
$25.3M Sell
390,231
-140,388
-26% -$9.07M 0.07% 494
2013
Q4
$31.5M Buy
530,619
+70,005
+15% +$3.8M 0.1% 309
2013
Q3
$23.9M Buy
460,614
+41,323
+10% +$2.08M 0.09% 338
2013
Q2
$19.8M Buy
+419,291
New +$21.4M 0.08% 339

Other funds holding AZN

Guggenheim Capital's AZN Position: Q1 2026 in Review

Guggenheim Capital reduced its AstraZeneca (AZN) stake by 86% in Q1 2026, selling an estimated $16.1M and leaving 14,101 shares worth $2.78M. The position accounts for 0.02% of the portfolio, ranked #606.

Guggenheim Capital first reported a position in AZN in Q2 2013 and has held it in 52 quarters since. The position peaked at $38.7M in Q3 2014. 1,377 funds tracked by Wall St. Rank hold AZN as of Q1 2026.

  • Guggenheim Capital held 14,101 shares of AstraZeneca worth $2.78M as of Q1 2026.
  • Guggenheim Capital sold 83,700 AstraZeneca shares in Q1 2026, an estimated $16.1M.
  • AstraZeneca made up 0.02% of Guggenheim Capital's portfolio in Q1 2026, its #606 holding.
  • Guggenheim Capital first reported a position in AstraZeneca in Q2 2013 and has held it in 52 quarters since.
  • Guggenheim Capital's AstraZeneca position peaked at $38.7M in Q3 2014.
  • 1,377 funds tracked by Wall St. Rank held AstraZeneca as of Q1 2026.

Based on Guggenheim Capital's 13F filing for Q1 2026, filed 15 May 2026.